Biogen's Vumerity and Bristol Myers Squibb's Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding Advantages Over Established AgentsPRNewsWire • 02/11/21
Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science StartupsGlobeNewsWire • 02/11/21
Biogen, Fortinet, Kohl's, Pinterest, Snap and More Friday Afternoon Analyst Calls24/7 Wall Street • 02/05/21
Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders OnlyGlobeNewsWire • 02/04/21
Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain InvestorsGlobeNewsWire • 02/04/21
Biogen Inc. (BIIB) CEO Michel Vounatsos on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/03/21
Biogen Crumbles; Disappointing 2021 Outlook Calls For A 'Sharp Decline'Investors Business Daily • 02/03/21
Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple SclerosisGlobeNewsWire • 02/01/21
Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week24/7 Wall Street • 01/31/21